Oncternal Therapeutics, Inc. announced the receipt of a 'Study May Proceed' letter from the U.S. Food and Drug Administration (FDA), 30 days after submitting its Investigational New Drug (IND) application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin's lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.25 USD | -6.04% | -12.33% | -23.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.07% | 25.99M | |
+43.75% | 56.65B | |
-7.03% | 39.44B | |
+38.99% | 39.03B | |
-11.17% | 26.86B | |
+13.01% | 26.75B | |
-21.84% | 19.03B | |
+1.28% | 12.28B | |
+24.70% | 12.26B | |
+27.35% | 12.04B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma